Evidence map›Paper›PMID 41257274›Full record

ArticleWorld journal of gastroenterology2025

Meng-Tzu Weng, Chi-Yuan Yao, Wei-Chen Lin, Sheng-Kai Lai, Chien-Chih Tung, Chun-Ying Wang, Jau-Min Wong, Pei-Lung Chen, Shu-Chen Wei

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. RevisitingWorld journal of gastroenterology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meng-Tzu WengDepartment of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
Chi-Yuan YaoDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
Wei-Chen LinDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan.
Sheng-Kai LaiDepartment of Medical Genetics, National Taiwan University Hospital, Taipei 100, Taiwan.
Chien-Chih TungDepartment of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei 100, Taiwan.
Chun-Ying WangDepartment of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu 302, Taiwan.
Jau-Min WongDepartment of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
Pei-Lung ChenDepartment of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
Shu-Chen WeiDepartment of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan. shuchenwei@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-drug antibodies (ADAs) can reduce the effectiveness of biologics. While human leukocyte antigen (HLA)-DQA1*05 allele is linked to ADA formation in European Crohn's disease patients, its relevance in non-European populations remains unclear.

aimTo investigate HLA genotypes associated with the development of ADAs in Taiwanese inflammatory bowel disease (IBD) patients treated with biologics.

methodsIn this multicenter study, IBD patients treated with anti-tumor necrosis factor (TNF), anti-integrin, or anti-interleukin (IL)-12/23 therapies from April 2022 to June 2024 were enrolled. All participants underwent next-generation sequencing for HLA genotyping. ADA levels were measured

resultsNinety-five IBD patients were included: 58 received anti-TNF therapy (38 infliximab, 20 adalimumab), 27 anti-integrin, and 10 anti-IL-12/23. ADAs occurred only in the anti-TNF group (

conclusionIn Taiwanese IBD patients,

Indexed as

HLA-C AntigensInflammatory Bowel DiseasesAdalimumabAdultBiological ProductsFemaleGene FrequencyGenotypeHLA-DQ alpha-ChainsHumansInfliximabMaleMiddle AgedTaiwanTumor Necrosis Factor-alphaYoung AdultAdalimumabBiological ProductsHLA-C AntigensHLA-DQA1 antigenHLA-DQ alpha-ChainsInfliximabTumor Necrosis Factor-alphaAnti-drug antibodiesAnti-tumor necrosis factor therapyCrohn’s diseaseHuman leukocyte antigen genotypeInflammatory bowel diseaseUlcerative colitis

Identifiers

PMID41257274
PMCPMC12620781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.